| Literature DB >> 34518157 |
Ryan Brown1, Azadeh Sharafi2, Jill M Slade3, Antonio Convit4,5, Nathan Davis6, Steven Baete2, Heather Milton7, Kenneth J Mroczek8, Patricia M Kluding9, Ravinder R Regatte2, Prodromos Parasoglou2, Smita Rao10.
Abstract
INTRODUCTION: The purpose of this study was to characterize using MRI the effects of a 10-week supervised exercise program on lower extremity skeletal muscle composition, nerve microarchitecture, and metabolic function in individuals with diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS: Twenty participants with DPN completed a longitudinal trial consisting of a 30-day control period, during which subjects made no change to their lifestyle, followed by a 10-week intervention program that included three supervised aerobic and resistance exercise sessions per week targeting the upper and lower extremities. The participants' midcalves were scanned with multinuclear MRI two times prior to intervention (baseline1 and baseline2) and once following intervention to measure relaxation times (T1, T1ρ, and T2), phosphocreatine recovery, fat fraction, and diffusion parameters.Entities:
Keywords: MRI; exercise; intervention; lower extremity
Mesh:
Year: 2021 PMID: 34518157 PMCID: PMC8438733 DOI: 10.1136/bmjdrc-2021-002312
Source DB: PubMed Journal: BMJ Open Diabetes Res Care ISSN: 2052-4897
Figure 1MRI data from a DPN patient in their 50s at baseline1 (first column), baseline2 (middle column), and postintervention (last column). Row 1 shows fat fraction maps and values in the interior ROI, row 2 shows measured gastrocnemius phosphocreatine levels (blue) and fitted mono-exponential resynthesis curves (red) and time constants during recovery following plantar flexion exercise, and row 3 shows ROIs. Similar fat fraction in the interior ROI and phosphocreatine recovery time constant are observed at baseline1 and baseline2, while reduced values are observed postintervention. DPN, diabetic peripheral neuropathy; ROI, region of interest.
Participant characteristics, intervention compliance, and clinical tests (n=20)
| Characteristic | Value | ||
| Age (years) | 60±6.9 | ||
| Sex (women/men) | 7/13 | ||
| Exercise sessions completed (%) | 89±12 | ||
| Time in exercise protocol (days) | 69±5 | ||
| Variation from heart rate goal (%) | −0.24±7.12 | ||
| Metric | Pre | Post | P value |
| BMI (kg/m2) | 31.3±4.4 | 30.5±4.1 | 0.139 |
| MNSI physical exam score | 2.9±1.0 | 2.9±1.7 | 0.950 |
| HbA1c (%) | 7.2±1.2 | 7.1±1.3 | 0.770 |
| Fasting glucose (mg/dL) | 139.7±47.5 | 143.4±45.9 | 0.616 |
| Glucose 120 min (mg/dL) | 265.0±104.8 | 257.6±106.0 | 0.378 |
| Matsuda index | 6.0±5.5 | 4.1±2.9 | 0.400 |
| HOMA-IR | 13.9±29.1 | 12.5±22.8 | 0.161 |
| C reactive protein (mg/L) | 4.4±3.7 | 4.7±4.5 | 0.693 |
| VO2peak (mL/kg/min) | 19.4±4.6 | 19.4±4.3 | 0.984 |
Pre indicates preintervention and post indicates postintervention. P indicates statistical differences between preintervention and postintervention values (paired, two-tailed Student’s t-test).
Two VO2 peak data sets were excluded due to scheduling and technical difficulties.
BMI, body mass index; HbA1c, glycosylated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; MNSI, Michigan Neuropathy Screening Instrument.
MRI results
| Metric | N | ROI | Baseline1 | Baseline2 | Pbase | Δbase (%) | Post | P value | Δpost (%) |
| FF (%) | 19 | Interior | 10.8±3.4 | 10.8±3.7 | 0.932 | 0.3±8.4 | 10.5±3.3 |
| −2.6±6.4 |
| 19 | GM | 8.6±4.6 | 8.5±4.0 | 0.733 | 1.7±11.3 | 8.4±4.0 | 0.564 | −1.8±8.7 | |
| 19 | GL | 7.4±4.0 | 7.6±3.8 | 0.402 | 3.9±11.6 | 7.5±3.9 | 0.520 | −2.5±12.0 | |
| 19 | SOL | 9.9±4.0 | 9.8±4.1 | 0.718 | −0.5±7.7 | 9.9±4.2 | 0.855 | 0.0±9.5 | |
| 15 | GM+GL | 34.1±20.6 | 35.4±21.8 | 0.551 | 7.4±27.4 | 32.3±21.7 | 0.309 | −4.6±30.2 | |
| FA | 17 | TN | 0.34±0.06 | 0.32±0.07 | 0.319 | −4.2±20.6 | 0.33±0.05 | 0.694 | 4.2±17.7 |
| ADC (x103 mm2/s) | 17 | TN | 1.77±0.31 | 1.76±0.20 | 0.922 | 2.0±20.4 | 1.81±0.19 | 0.463 | 3.9±16.6 |
| T1 (ms) | 12 | GM | 940.9±43.3 | 918.3±20.0 |
| −2.3±3.0 | |||
| 12 | GL | 947.5±42.4 | 935.0±18.7 | 0.274 | −1.2±3.8 | ||||
| 12 | SOL | 938.3±34.4 | 935.7±23.6 | 0.727 | −0.2±2.7 | ||||
| T1ρ (ms) | 12 | GM | 31.0±3.7 | 29.6±1.8 |
| −4.1±7.7 | |||
| 12 | GL | 30.0±4.5 | 29.1±2.0 | 0.365 | −1.8±10.6 | ||||
| 12 | SOL | 31.7±3.0 | 31.6±2.8 | 0.974 | 0.2±7.3 | ||||
| T2 (ms) | 12 | GM | 25.3±2.6 | 24.2±1.2 |
| −3.5±6.4 | |||
| 12 | GL | 26.6±2.7 | 25.2±1.8 |
| −4.6±7.4 | ||||
| 12 | SOL | 23.9±1.3 | 23.1±1.4 |
| −3.2±3.1 |
Pbase indicates statistical differences between baseline1 and baseline2 values (paired, two-tailed Student’s t-test). P indicates differences between baseline2 and postintervention values. P values in bold type indicate statistically significant differences or trends toward significance (p<0.1).
ADC, apparent diffusion coefficient; Δbase, percentage change between baseline1 and baseline2 values; FA, fractional anisotropy; FF, fat fraction; GL, gastrocnemius lateralis; GM, gastrocnemius medialis; Δpost, percentage change between baseline2 and postintervention values; post, postintervention; ROI, region of interest; SOL, soleus; TN, tibial nerve.
Significant associations (p<0.05) between preintervention and postintervention percentage based changes in MRI and clinical variables
| MRI measurement | ROI | Clinical measurement | N | rs | P value |
| FF | Interior | HbA1c | 19 | −0.459 | 0.048 |
| T1 | GM | VO2peak | 11 | 0.646 | 0.037 |
| T1ρ | GM | VO2peak | 11 | 0.800 | 0.005 |
| T2 | GL | VO2peak | 11 | 0.627 | 0.044 |
| T2 | SOL | MNSI physical exam score | 12 | 0.587 | 0.045 |
FF, fat fraction; GL, gastrocnemius lateralis; GM, gastrocnemius medialis; HbA1c, glycosylated hemoglobin; MNSI, Michigan Neuropathy Screening Instrument; ROI, region of interest; SOL, soleus.